4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immunome, Inc. (IMNM) operates in the Biotechnology industry and is headquartered in Bothell, United States with about 206 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, IMNM reported $7M in revenue and ($212M) in net income.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Interactive charts & full statements → Open the IMNM valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $7M | $9M | $14M | $0M | — |
| Operating Income (EBIT) | ($224M) | ($154M) | ($29M) | ($37M) | — |
| Net Income | ($212M) | ($293M) | ($107M) | ($37M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $4M | $3M | — |
| Operating Income (EBIT) | ($59M) | ($73M) | ($60M) | ($46M) | ($45M) | — |
| Net Income | ($54M) | ($70M) | ($58M) | ($43M) | ($42M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $683M | $240M | $148M | $24M | — |
| Total Liabilities | $49M | $59M | $29M | $7M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IMNM viewer.
About TickerBase · Data methodology & sources